Overview
AlgoSurg Inc is a Mumbai-based medtech-AI startup that converts 2D X-ray images into 3D bone models for surgical planning. Founded by Dr. Vikas Karade and Amit Maurya, the company emerged from Karade's PhD research at IIT-Bombay, joined Y Combinator's Winter 2018 batch, and built a portfolio of AI-powered planning tools licensed to implant OEMs like Meril and SH Pitkar. The company claims 15,000+ surgeries powered and 500+ surgeons served across knee replacement, trauma, robotic surgery, and structural heart applications.[12]
AlgoSurg's failure is not a story of bad technology — its clinical validation is real — but of a structural mismatch between its business model and its funding base. The company built a B2B2C licensing model that made it dependent on a handful of OEM partners with multi-year regulatory timelines, while operating on roughly $120K in total funding — a sum that cannot sustain a medtech company through FDA/CE approval cycles that typically cost millions.[6] The result is a "zombie" startup: still listed as active, still technically operating, but with no visible growth trajectory, no follow-on funding, and no path to the scale its investors would have required.
Image 1 / 3
Founding Story
AlgoSurg's origin traces to a conversation Karade overheard during his PhD at IIT-Bombay. As he told the Economic Times: "During my time at IIT-Bombay, I stumbled upon a discussion between some top orthopaedic surgeons about the practicality of converting a 2D X-ray image into a 3D model for a bone. I took it up as part of my PhD research, and under their mentorship, developed an algorithm that took us a step closer to solving this problem."[2]
That algorithm became XrayTo3D, the foundation of AlgoSurg. Karade, who holds a PhD from IIT-Bombay, teamed up with Amit Maurya, his college batchmate with over a decade of experience in medical software development, AI/ML medical image processing, surgical simulations, and FDA regulatory work.[1] The company was incorporated as AlgoSurg Products Pvt Ltd in Mumbai in February 2016.[3]
The founding story carries a distinctly Indian flavor of institutional validation. In 2015, before formal incorporation, AlgoSurg was part of the 40-startup consortium that accompanied PM Narendra Modi to Silicon Valley — a remarkable early credential.[3] In February 2017, the company won The American Bazaar Startup Competition in Mumbai, beating 21 other startups and earning the opportunity to pitch US investors.[4] The technology was developed at SINE, IIT-Bombay's Society of Innovation and Entrepreneurship incubator.[26]
The company's early validation was strong: clinical mentorship from top orthopaedic surgeons, government grants from BIRAC and the Department of Science and Technology, and a Y Combinator acceptance in Winter 2018.[6] But the funding base never matched the ambition. Total funding was approximately Rs 1 crore (~$120K) — a figure that would prove catastrophically insufficient for the regulatory burden the company's product strategy required.[6]
Timeline
- 2015: AlgoSurg joins PM Modi's 40-startup delegation to Silicon Valley, gaining early visibility.[3]
- February 2016: AlgoSurg incorporated as 'AlgoSurg Products Pvt Ltd' in Mumbai.[3]
- February 2017: Wins The American Bazaar Startup Competition in Mumbai, beating 21 startups.[4]
- December 2017: Economic Times feature highlights XrayTo3D technology and 20x cost advantage over CT.[5]
- 2018: Accepted into Y Combinator Winter 2018 batch; raises pre-seed with YC as lead.[0]
- September 2018: X3DPSI clinical trial registered in Clinical Trials Registry of India (CTRI/2018/09...).[26]
- February 2022: Clinical study published in Indian Journal of Orthopaedics showing X3DPSI improves alignment vs. conventional instruments in TKA.[16]
- July 2025: Founder interview with Center for Data Innovation; company still active but no new funding news.[13]
What They Built
AlgoSurg's core product, Tabplan3D, is a cloud-based 3D surgery planning software that converts simple 2D X-ray images into 3D bone models using a patented machine learning algorithm. The company claims this is "20 times more costly" to do with CT scans, which also involve toxic radiation dosage.[5] The technical foundation is an enhanced version of nnU-Net, a leading architecture for medical image segmentation, applied via convolutional neural networks.[13]
The user experience is designed around speed and accessibility. As Karade explained: "A CT-based 3D solution that entails designing patient-specific instruments (PSI) is a manual process that takes weeks and needs the assistance of a clinical engineer. Our X-ray based software performs the same tasks (except 3D printing of PSI) in a minute without any external help."[23] In knee replacement surgery, the system automatically generates 3D bone models and marks reference points, reducing planning time from hours to minutes.[15]
The product portfolio expanded across multiple surgical verticals:
- X3DPSI for knee replacement — X-ray-based patient-specific instruments, clinically validated in a 2022 study.[16]
- DeftFix for trauma — a cloud planner for hexapod fixators, FDA-approved (US-FDA 510K) and licensed by SH Pitkar.[10]
- MISSO for robotic surgery — integrated into Meril's next-gen robotic joint replacement system, EU-MDR approved with US-FDA submission in progress.[9]
- TAVR for structural heart — automated 3D planning, licensed by a leading global TAVR implant OEM.[17]
- CMF for maxillofacial surgery — AI platform for planning and 3D printing, with pilots ongoing with global 3D printing firms.[18]
- OpenSurgiSim — a cloud + AR training platform for surgeons in low and middle-income countries, funded by the Intuitive Foundation.[11]
Karade described the company's differentiation: "Many medical AI tools solve only part of the problem. AlgoSurg delivers an end-to-end solution, from image segmentation to 3D modeling, identification, and surgical tool design. We've also optimized the platform for robotic surgery and 3D printing."[14]
The breadth is technically impressive but strategically problematic. Each vertical requires its own regulatory approval, its own OEM partnership, and its own clinical validation. For a team of eight people operating on $120K, this is not focus — it is fragmentation.
Market Position
Target Customers
AlgoSurg's business model is B2B2C: licensing its AI planning software to implant OEMs (Meril, SH Pitkar), robotic platforms, and 3D printing providers, rather than selling directly to hospitals or surgeons.[20] The end users are orthopaedic surgeons, but the buyers are device manufacturers who integrate AlgoSurg's planning tools into their own products.
Market Size
The Indian market for knee replacement is substantial: Karade stated that more than 250,000 arthritic patients need knee replacement surgeries every year in India.[22] The value proposition is compelling: X-ray-based planning is faster (minutes vs. weeks) and cheaper than CT-based PSI, with a claimed 20x cost advantage.[5]
Competition
The competitive landscape for surgical planning AI is dominated by two structural forces that AlgoSurg could not overcome.
First, the incumbents — Materialise, Stryker, Zimmer Biomet — already own the distribution channels. Stryker and Zimmer Biomet are implant OEMs themselves; they don't need to license planning software from a startup when they can build it into their own platforms. Materialise has spent decades building medical 3D printing and planning software with deep regulatory expertise. AlgoSurg's technology was a feature that OEMs could absorb, not a standalone product that could command standalone pricing.
Second, the platform shift: robotic surgery systems like Stryker's Mako and Zimmer's Rosa are increasingly bundling AI-powered planning natively. When the robot manufacturer controls both the hardware and the planning software, there is no room for a third-party planner. AlgoSurg's licensing deal with Meril's MISSO robotic system is telling — it positions AlgoSurg as a component supplier to a robot that competes with Mako, not as a platform in its own right.
The company's position was structurally weak: it competed on product depth (X-ray-based planning) against incumbents with distribution reach (OEMs with sales forces and regulatory teams) and platform control (robotic systems that bundle planning natively). AlgoSurg's technology was good enough to license, but not differentiated enough to command the economics of a standalone business.
Business Model
AlgoSurg's revenue model was licensing: implant OEMs, robotic platforms, and 3D printing providers paid to integrate AlgoSurg's AI planning software into their products.[20] The company claimed 15,000+ surgeries powered and 500+ surgeons served, with 200+ surgical robots using their AI.[12]
The company never disclosed revenue figures, pricing models, or contract terms. The absence of revenue data is itself a signal: if AlgoSurg had meaningful recurring revenue, it would have been a fundraising story. Instead, the company's Crunchbase profile lists four funding rounds (grants, angel, pre-seed) with Y Combinator as lead in the pre-seed — and then nothing.[7]
The unit economics are inferable from the funding data. With ~$120K total funding and a team of eight, AlgoSurg's annual burn was likely in the range of $50-80K in India — meaning the company had roughly 1.5-2 years of runway from its entire funding history.[6] That is not enough to take a single product through FDA approval, let alone the six verticals the company pursued.
The licensing model also created a structural problem: OEMs saw AlgoSurg as a vendor to acquire or replicate, not a partner to fund. When Meril integrates AlgoSurg's planning into MISSO, Meril captures the value; AlgoSurg gets a licensing fee but no equity upside and no direct relationship with the surgeon end-user.
Traction
AlgoSurg's traction is real but modest, and almost entirely self-reported. The company claims 15,000+ surgeries powered, 500+ surgeons served, and 200+ surgical robots using their AI.[12] The DeftFix trauma planner is FDA-approved (US-FDA 510K) and licensed by SH Pitkar, with thousands of surgeries done globally.[10] The Meril MISSO robotic system is EU-MDR approved, with a planned deployment of around 1,000 licenses over the next 3-5 years and US-FDA submission in progress.[9]
The clinical validation is the strongest evidence of real capability. A 2022 study in the Indian Journal of Orthopaedics compared AlgoSurg's X3DPSI against conventional instruments in total knee arthroplasty. The study of 10 patients found that mechanical axis alignment achieved with X3DPSI was significantly better than with conventional instruments in terms of both HKA angle and MAD.[16]
But the numbers tell a cautionary tale. Ten patients is a pilot, not a pivotal trial. The clinical trial registry entry planned for 65 patients total across multiple phases.[26] The company's own claims of 15,000+ surgeries are not independently verified. And the most recent public milestone — a 2025 founder Q&A with the Center for Data Innovation — is a thought-leadership piece, not a product launch or funding announcement.[13]
Post-Mortem
The funding gap was the original sin
AlgoSurg's most fundamental problem was that its funding base was never commensurate with the regulatory burden of medical devices. The company raised approximately Rs 1 crore (~$120K) from government grants and equity investments, including BIRAC, DST, SINE IIT-Bombay, and Y Combinator.[6] That is a seed-stage sum for a software startup — but AlgoSurg was not a software startup. It was a medical device company that needed to navigate FDA 510K submissions, EU-MDR certification, and clinical trials across multiple surgical verticals.
The math is unforgiving. A single FDA 510K submission costs hundreds of thousands of dollars in regulatory consulting, testing, and documentation. A clinical trial for a Class II medical device costs more. AlgoSurg's entire funding base would not cover the regulatory costs of one product, let alone the six verticals it pursued. The company's Crunchbase profile lists four funding rounds — grants, angel, pre-seed — and then nothing.[7] No Series A. No Series B. No bridge round. The absence of follow-on funding is the clearest signal that investors did not see a path to outsized returns.
The B2B2C licensing model created dependency without scale
AlgoSurg's business model was structurally dependent on a handful of OEM partners. The company licensed its technology to Meril for robotic surgery, SH Pitkar for trauma fixators, and a leading global TAVR implant OEM for structural heart.[9] Each of these deals has a long sales cycle, a regulatory approval process, and a deployment timeline measured in years, not quarters.
The Meril deal illustrates the problem. MISSO is EU-MDR approved, with a planned deployment of around 1,000 licenses over the next 3-5 years and US-FDA submission in progress.[9] That means AlgoSurg's revenue from its flagship robotic surgery deal is spread across a multi-year timeline, with the US market — the largest and most valuable — still pending regulatory approval. For a company with $120K in total funding, waiting 3-5 years for a licensing deal to scale is not a strategy; it is a death sentence.
The licensing model also meant AlgoSurg had no direct relationship with its end users. The surgeons who used AlgoSurg's technology were Meril's customers, not AlgoSurg's. The company could not upsell, cross-sell, or build a direct channel to the 500+ surgeons it claimed to serve.[12] It was a component supplier in a market where the OEMs controlled the customer relationship, the pricing, and the regulatory pathway.
The product breadth was a strategic error
AlgoSurg's portfolio spanned knee replacement, trauma, robotic surgery, structural heart, maxillofacial, and surgical training.[9] Each vertical required its own regulatory approval, its own OEM partnership, and its own clinical validation. For a team of eight people, this was not ambition — it was fragmentation.
The company never established a dominant beachhead. X3DPSI for knee replacement was the most clinically validated product, but the clinical study was small (10 patients) and the market was already served by CT-based PSI from incumbents like Materialise and Zimmer Biomet.[16] DeftFix was FDA-approved but in a niche trauma market. MISSO was promising but dependent on Meril's execution. TAVR and CMF were still in trials and pilots.
The structural mechanism here is the "feature absorption" problem. AlgoSurg's technology was genuinely useful, but it was a feature that OEMs could — and did — absorb into their own platforms. When Meril integrates AlgoSurg's planning into MISSO, Meril captures the value. When a TAVR OEM licenses AlgoSurg's planning, the OEM owns the customer. AlgoSurg was building the components for other companies' products, and those companies had no incentive to fund AlgoSurg's growth — they had every incentive to replicate the technology internally or acquire it cheaply.
The counterargument: AlgoSurg may not be dead
The strongest counterargument to the failure thesis is that AlgoSurg is still operating. The company's website is active, the 2025 founder interview with the Center for Data Innovation suggests ongoing operations, and the licensing deals with Meril and SH Pitkar are real, with FDA-approved products.[13] Karade's 2025 comments describe a company with a clear vision: "We use convolutional neural networks, deep learning models capable of interpreting complex images. Our models build on an enhanced version of nnU-Net, a leading architecture for medical image analysis."[13]
But even if AlgoSurg is alive, it has not achieved the scale typical of a YC-backed startup. The company is still listed as "Active" on YC and Crunchbase, but the lack of new funding rounds, the absence of investor commentary, and the fact that the most recent press is a founder Q&A rather than product news all suggest stagnation rather than growth.[0] The company's own Crunchbase profile claims: "With ongoing U.S. expansion and FDA pathways underway, AlgoSurg is positioned to transform global surgical workflows."[25] That language is aspirational, not operational.
The deeper question is whether AlgoSurg's technology was ever going to be a standalone business. The answer, given the evidence, is probably not. The company built a clinically validated, technically impressive product suite — but in a market where the OEMs control the distribution, the regulatory pathway, and the customer relationship, a small startup with $120K in funding was never going to win. The technology was real; the business model was not.
Key Lessons
-
Regulatory burden must match funding base. AlgoSurg raised ~$120K to build a medical device company requiring FDA/CE approvals across multiple verticals.[6] The math was never viable. A medtech AI startup needs either massive capital or a single, focused product with a fast regulatory path — not six verticals on a seed-stage budget.
-
B2B2C licensing to OEMs is a feature, not a business. When AlgoSurg licensed its planning software to Meril and SH Pitkar, it became a component supplier in someone else's product.[9] The OEMs captured the customer relationship, the pricing power, and the value. A startup that sells to OEMs is building a feature for the OEM's platform — and the OEM will eventually replicate or acquire that feature rather than fund its growth.
-
Product breadth without a beachhead is fragmentation. AlgoSurg pursued knee replacement, trauma, robotic surgery, structural heart, maxillofacial, and training simultaneously.[9] Each vertical required its own regulatory approval and OEM partnership. The company never established a dominant position in any single market, which made it hard to attract the follow-on funding needed to scale any of them.
-
Clinical validation is necessary but not sufficient. The 2022 study showing X3DPSI improved alignment was real evidence of capability.[16] But a 10-patient study is a pilot, not a pivotal trial, and clinical validity does not translate into commercial viability without a distribution channel. AlgoSurg had the former but never built the latter.
Sources
- Y Combinator — AlgoSurg Inc
- Economic Times — From impressing the President to PM Modi: A startup's cure for knee replacement surgery is 20x cheaper
- Economic Times — AlgoSurg incorporation and PM Modi delegation
- The American Bazaar — AlgoSurg wins startup competition
- Economic Times — XrayTo3D technology and 20x cost advantage
- YourStory — AlgoSurg company profile
- Crunchbase — AlgoSurg
- AlgoSurg — About page
- AlgoSurg — Products page (Meril MISSO)
- AlgoSurg — Products page (DeftFix)
- AlgoSurg — Products page (OpenSurgiSim)
- AlgoSurg — Homepage
- Center for Data Innovation — 5 Questions with Dr. Vikas Karade, CEO AlgoSurg
- Center for Data Innovation — Karade on end-to-end solution
- Center for Data Innovation — Karade on knee replacement impact
- ResearchGate — A Study of Surgical Accuracy with X-Ray-Based Patient-Specific Instrument X3DPSI vs Conventional Instrument in Total Knee Arthroplasty Surgeries
- AlgoSurg — Products page (TAVR)
- AlgoSurg — Products page (CMF)
- AlgoSurg — Homepage (Gen-3 vision)
- AlgoSurg — About page (company description)
- AlgoSurg — About page (team)
- Economic Times — Karade on 250,000 knee replacements
- Economic Times — Karade on CT-based vs X-ray-based PSI
- Crunchbase — AlgoSurg profile
- Crunchbase — AlgoSurg US expansion claim
- ResearchGate — X3DPSI clinical trial registration
- AlgoSurg — Homepage (partners)
- AlgoSurg — Products page (licensed technology)